Name Eligible Study sites More information
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis 18 years of age or older at the time of signing the informed consent. Body weight ≥ 30 kilograms at the time of Screening. Male or female. see more details Sites in US, Italy, Korea and Spain More details; Alexion Pharmaceuticals, Inc; 855-752-2356; NCT04999020
Abatacept (Orencia) Active DM/PM/NM/JDM (over 18), overlap 78 sites in US, Australia, S. America, Asia, Europe More details; BMS StudyConnect; NCT02971683
Abatacept for treatment of myositis-associated interstitial lung disease (Attack My-ILD) ILD + antisynthetase antibody (Jo-1, PL-7, PL-12, EJ, OJ, KS) Los Angeles, CA, Denver, CO, Baltimore, MD, Boston, MA, Pittsburgh, PA More details; Courtney Ward 412-648-9989; NCT03215927
KZR-616 Active, Not Recruiting
10 sites in US More details; 650-822-5600; NCT04033926
Lenabasum Adults with DM 45 US cities More details; Lindsey Smith 1-617-963-0707; NCT03813160
PF-06823859 DM 30 sites in the US, EU and Australia More details; 1-800-718-1021; NCT03181893
Rituximab vs Cyclophospahamide in Connective Tissue Disease-ILD (RECITAL) DM, PM, MCTD + ILD London, UK More details; Toby M Maher 02073518018; NCT01862926
Sodium thiosulfate for treatment of calcinosis associated with juvenile and adult dermatomyositis DM and JDM with calcinosis National Institutes of Health, Bethesda, MD More details; Adam Schiffenbauer 301-451-6270; NCT03267277
Safety and Efficacy Study of Zilucuplan in Subjects with Immune-Mediated Necrotizing Myopathy Adults over the age 18 with Immune-Mediated Necrotizing Myopathy and are positive for HMGCR or SRP autoantibodies US States:  CA, FL, KS, MA, OH, PA and TN
International:  UK
More Details;
IgPro20 (Hizentra) Active DM, ADM (over 18) 94 sites in US, Australia, Japan, Argentina, Mexico, Europe, Ukraine, Russia More details; Trial Registration Coordinator 610-878-4000; NCT04044690


For persons recently diagnosed with AntiHMG Auto-Antibody Positive Necrotizing Myopathy (HMGCR Myopathy) 2 sites in US, Seattle,  WA and Baltimore, MD More details; Research Coordinator, Leslie Lazar Thorn, 206-744-9143 / 206-295-4425,